Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

Zhejiang University

Status: Enrolling

Conditions: Janus Kinase Inhibitors; Alopecia Areata

Treatments: Drug: Ritlecitinib; Drug: Abrocitinib; Drug: Ruxolitinib; Drug: Baricitinib; Drug: Upadacitinib; Drug: Tofacitinib

Study type: Observational

Funder types: Other

Identifiers

NCT06573593

20240699

Details and patient eligibility

About

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Enrollment: 150 estimated patients

Sex: All

Ages: 2 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with alopecia areata between 2 to 18 years old
• Patients diagnosed with alopecia areata according to AA guideline
• AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months

Exclusion criteria

• Patients had previously received hair implants
• Other alopecia
• Other diseases may induce alopecia including psoriasis, lichen planus, et al.
• Unable to estimate SALT score at baseline or at follow-up
• Patients are participating in other clinical trials

Trial design

150 participants in 6 patient groups

Tofacitinib treated group

Description:

In the real-world settings, patients with AA treated with tofacitinib.

Treatment:

Drug: Tofacitinib

Baritinib treated group

Description:

In the real-world settings, patients with AA treated with baritinib.

Treatment:

Drug: Baricitinib

Ruxolitinib treated group

Description:

In the real-world settings, patients with AA treated with ruxolitinib

Treatment:

Drug: Ruxolitinib

Upadacitinib treated group

Description:

In the real-world settings, patients with AA treated with upadacitinib.

Treatment:

Drug: Upadacitinib

Abrocitinib treated group

Description:

In the real-world settings, patients with AA treated with abhicitinib.

Treatment:

Drug: Abrocitinib

Ritlecitinib treated group

Description:

In the real-world settings, patients with AA treated with ritlecitinib.

Treatment:

Drug: Ritlecitinib